Natural history of hyperlactataemia in human immunodeficiency virus-1-infected patients during highly active antiretroviral therapy

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 1, 2003, Pages 62-66

  Huynh, Tuan K ^a   Lüttichau, Hans R ^a   Roge, Birgit T ^a   Gerstoft, Jan ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LACTIC ACID; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; DENMARK; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIPOATROPHY; LIVER DYSFUNCTION; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NEUROPATHY; OUTPATIENT DEPARTMENT; PANCREATITIS; PATIENT MONITORING; PERIPHERAL NEUROPATHY;

ACIDOSIS, LACTIC; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; LACTATES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; RISK FACTORS; VIRAL LOAD;

EID: 0037226226     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/0036554021000026992     Document Type: Article

References (17)

1. Gerard Y, Maulin L, Yazdanpanah Y, De LTX, Amiel C, Maurage CA, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000; 14: 2723-30.
2. Brinkman K. Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis 2000; 31: 167-9.
3. Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001; 33: 1914-21.
4. Carr A, Morey A, Mallon P, Williams D, Thorburn DR. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 2001; 357: 1412-24.
5. Bleeker-Rovers CP, Kadir SW, van Leusen R, Richter C. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient. Neth J Med 2000; 57: 190-3.
6. Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 2000; 30: 198-200.
7. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-44.
8. Reliquet V, Mussini JM, Chennebault JM, Lafeuillade A, Raffi F. Peripheral neuropathy during stavudine-didanosine antiretroviral therapy. HIV Med 2001; 2: 92-6.
9. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-5.
10. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717-23.
11. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33: 1931-7.
12. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358: 1322-7.
13. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14: F25-32.
14. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31: 162-6.
15. ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000; 11: 611-6.
16. Walker UA, Brinkman K. NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact or fiction? HIV Med 2001; 2: 163-5.
17. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001; 15: 795-7.